276 related articles for article (PubMed ID: 37433987)
21. No small surprise - small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour.
Foulkes WD; Clarke BA; Hasselblatt M; Majewski J; Albrecht S; McCluggage WG
J Pathol; 2014 Jul; 233(3):209-14. PubMed ID: 24752781
[TBL] [Abstract][Full Text] [Related]
22. Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers.
Hodges HC; Stanton BZ; Cermakova K; Chang CY; Miller EL; Kirkland JG; Ku WL; Veverka V; Zhao K; Crabtree GR
Nat Struct Mol Biol; 2018 Jan; 25(1):61-72. PubMed ID: 29323272
[TBL] [Abstract][Full Text] [Related]
23. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.
Ramalingam P; Croce S; McCluggage WG
Histopathology; 2017 Feb; 70(3):359-366. PubMed ID: 27656868
[TBL] [Abstract][Full Text] [Related]
24. Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome.
Foulkes WD; Kamihara J; Evans DGR; Brugières L; Bourdeaut F; Molenaar JJ; Walsh MF; Brodeur GM; Diller L
Clin Cancer Res; 2017 Jun; 23(12):e62-e67. PubMed ID: 28620006
[TBL] [Abstract][Full Text] [Related]
25. Brain and Spinal Cord Tumors of Embryonic Origin.
Lampros M; Alexiou GA
Adv Exp Med Biol; 2023; 1405():405-420. PubMed ID: 37452947
[TBL] [Abstract][Full Text] [Related]
26. Germline pathogenic
Witkowski L; Nichols KE; Jongmans M; van Engelen N; de Krijger RR; Herrera-Mullar J; Tytgat L; Bahrami A; Mar Fan H; Davidson AL; Robertson T; Anderson M; Hasselblatt M; Plon SE; Foulkes WD
J Med Genet; 2023 Oct; 60(10):987-992. PubMed ID: 36813544
[TBL] [Abstract][Full Text] [Related]
27. The ATPase BRG1/SMARCA4 is a protein interaction platform that recruits BAF subunits and the transcriptional repressor REST/NRSF in neural progenitor cells.
Jayaprakash S; Drakulic S; Zhao Z; Sander B; Golas MM
Mol Cell Biochem; 2019 Nov; 461(1-2):171-182. PubMed ID: 31428904
[TBL] [Abstract][Full Text] [Related]
28. SMARCA4-Mutated Atypical Teratoid/Rhabdoid Tumor with Retained BRG1 Expression.
Masliah-Planchon J; Machet MC; Fréneaux P; Jourdain A; Mortemousque I; Raïs KA; Ballet S; Jouvet A; Figarella-Branger D; Delattre O; Bourdeaut F
Pediatr Blood Cancer; 2016 Mar; 63(3):568-9. PubMed ID: 26469284
[No Abstract] [Full Text] [Related]
29. SMARCA4 regulates gene expression and higher-order chromatin structure in proliferating mammary epithelial cells.
Barutcu AR; Lajoie BR; Fritz AJ; McCord RP; Nickerson JA; van Wijnen AJ; Lian JB; Stein JL; Dekker J; Stein GS; Imbalzano AN
Genome Res; 2016 Sep; 26(9):1188-201. PubMed ID: 27435934
[TBL] [Abstract][Full Text] [Related]
30. SMARCA4-Deficient Undifferentiated Tumor of Lung Mass-A Rare Tumor With the Rarer Occurrence of Brain Metastasis: A Case Report and Review of the Literature.
Yadav R; Sun L; Salyana M; Eric M; Gotlieb V; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221074864. PubMed ID: 35356840
[TBL] [Abstract][Full Text] [Related]
31. SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome.
Hasselblatt M; Thomas C; Federico A; Nemes K; Johann PD; Bison B; Bens S; Dahlum S; Kordes U; Redlich A; Lessel L; Pajtler KW; Mawrin C; Schüller U; Nolte K; Kramm CM; Hinz F; Sahm F; Giannini C; Penkert J; Kratz CP; Pfister SM; Siebert R; Paulus W; Kool M; Frühwald MC
Am J Surg Pathol; 2022 Sep; 46(9):1277-1283. PubMed ID: 35446794
[TBL] [Abstract][Full Text] [Related]
32. Autism-Associated Chromatin Regulator Brg1/SmarcA4 Is Required for Synapse Development and Myocyte Enhancer Factor 2-Mediated Synapse Remodeling.
Zhang Z; Cao M; Chang CW; Wang C; Shi X; Zhan X; Birnbaum SG; Bezprozvanny I; Huber KM; Wu JI
Mol Cell Biol; 2016 Jan; 36(1):70-83. PubMed ID: 26459759
[TBL] [Abstract][Full Text] [Related]
33. Novel mutations target distinct subgroups of medulloblastoma.
Robinson G; Parker M; Kranenburg TA; Lu C; Chen X; Ding L; Phoenix TN; Hedlund E; Wei L; Zhu X; Chalhoub N; Baker SJ; Huether R; Kriwacki R; Curley N; Thiruvenkatam R; Wang J; Wu G; Rusch M; Hong X; Becksfort J; Gupta P; Ma J; Easton J; Vadodaria B; Onar-Thomas A; Lin T; Li S; Pounds S; Paugh S; Zhao D; Kawauchi D; Roussel MF; Finkelstein D; Ellison DW; Lau CC; Bouffet E; Hassall T; Gururangan S; Cohn R; Fulton RS; Fulton LL; Dooling DJ; Ochoa K; Gajjar A; Mardis ER; Wilson RK; Downing JR; Zhang J; Gilbertson RJ
Nature; 2012 Aug; 488(7409):43-8. PubMed ID: 22722829
[TBL] [Abstract][Full Text] [Related]
34. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features.
Kinoshita F; Kohashi K; Sugimoto M; Takamatsu D; Kiyozawa D; Eto M; Oda Y
Virchows Arch; 2020 Nov; 477(5):651-660. PubMed ID: 32447490
[TBL] [Abstract][Full Text] [Related]
35. SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type.
Errichiello E; Mustafa N; Vetro A; Notarangelo LD; de Jonge H; Rinaldi B; Vergani D; Giglio SR; Morbini P; Zuffardi O
J Pathol; 2017 Sep; 243(1):9-15. PubMed ID: 28608987
[TBL] [Abstract][Full Text] [Related]
36. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome.
Schneppenheim R; Frühwald MC; Gesk S; Hasselblatt M; Jeibmann A; Kordes U; Kreuz M; Leuschner I; Martin Subero JI; Obser T; Oyen F; Vater I; Siebert R
Am J Hum Genet; 2010 Feb; 86(2):279-84. PubMed ID: 20137775
[TBL] [Abstract][Full Text] [Related]
37. A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.
Peng L; Li J; Wu J; Xu B; Wang Z; Giamas G; Stebbing J; Yu Z
Front Immunol; 2021; 12():762598. PubMed ID: 34675941
[TBL] [Abstract][Full Text] [Related]
38. Loss of BRG1 (
Saunders J; Ingley K; Wang XQ; Harvey M; Armstrong L; Ng T; Dunham C; Bush J
Pediatr Dev Pathol; 2020; 23(2):132-138. PubMed ID: 31403913
[TBL] [Abstract][Full Text] [Related]
39. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
40. Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia.
Rago F; Rodrigues LU; Bonney M; Sprouffske K; Kurth E; Elliott G; Ambrose J; Aspesi P; Oborski J; Chen JT; McDonald ER; Mapa FA; Ruddy DA; Kauffmann A; Abrams T; Bhang HC; Jagani Z
Mol Cancer Res; 2022 Mar; 20(3):361-372. PubMed ID: 34799403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
